In this setting, the expression of PD-L1 on cancer cells could not predict responses to pembrolizumab, in that some tumors expressed PD-L1 did not respond, and some responses occurred in PD-L1–negative tumors (Fig. 5a, b), in consistence with a previous report12. Here, CD274 is linked to cancer.